User Viewpoints on Disposables Implementation - What end users think about single-use systems. - BioPharm International

ADVERTISEMENT

User Viewpoints on Disposables Implementation
What end users think about single-use systems.


BioPharm International
Volume 22, Issue 6


Miriam Monge
The industry is in transition. There is a renewed focus on cost and efficiency, and as a resilt, we are seeing a major uptake in the use of disposables technologies. The opportunities provided by disposable technologies also come with risks, however, and single-use technologies are not a homogenous toolkit that provide a simple fix. Rather, the market offers a mixture of technologies at different states of maturity from a wide variety of suppliers. This variability poses challenges in terms of supply chain and technical risk. In this article, we present the end-user perspective. Since the last column, we have visited Interphex in New York, and talked to a number of industry leaders from the manufacturing and contracting manufacturing sectors for their perspectives on the real concerns arising from the adoption of disposable technologies for the commercial manufacture of biotech products.

CHALLENGES AND OPPORTUNITIES

When we discussed the challenges and opportunities posed by disposable technologies, we asked a number of questions. Do disposables really change the way end users look at and manage operations? Do disposables technologies change the way they view and operate the factory? How can the opportunities be maximized, and the downsides be minimized?

Challenges. From these conversations, several key challenges emerged.


Andrew Sinclair
Cost. There are significant differences in the announced pricing from one supplier to another. Many suppliers try to play on the fact that they have a unique technology and accordingly charge a significant premium, whereas others take a pragmatic approach, thinking about long-term relationships. One interviewee said that cost does indeed matter. "The end-user may appreciate a new disposable technology for the benefits it brings in terms of simplifying equipment preparation, cleaning, etc., but will not adopt this technology if it actually works out [to be] more expensive than the technology the end-user was working with previously," he said.

Quality and reliability. By moving to disposables, the end user is effectively outsourcing a major part of manufacturing and quality management. As a result, the user must work very closely with the supplier to ensure that robust quality throughout the manufacturing process is maintained.

Supply chain. Supply chain risk is a common sourse of complaints related to dual sourcing and consistency of supply. One user commented that his (her) company's zero change policy requires careful planning. "We ask our disposable suppliers contractually for a guarantee of supply without change for a 5–10 year period," he (she) said. Such a policy means that the user has to consider the supply chain in most minute detail in terms of component and film suppliers and ensure that all the necessary contracts are in place.

Ergonomics. One user noted the operator's role in terms of handling of large-scale containers and the manipulation of tubing sets. "When working with disposables, there is a much greater dependence on the operators themselves. If they make a manipulation error, this could contaminate the whole process," he said. "We work with our suppliers in designing disposable systems that are as intuitive as possible, are idiot-proof, and so minimize the risk of operator error."

Opportunities. The opportunities presented by single-use technologies for manufacturing tend to relate to flexibility of operation, ease of product changeover, and the removal of wasted activities in terms of preparation and cleaning. "The great opportunity with disposables is that we can spend more time concentrating on manufacturing steps, the productive steps, and get rid of preparation work," said one interviewee. Users also see significant benefit from disposables when applied to process development, where fast turnaround in pilot and clinical supply facilities are extremely important.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here